Cargando…

What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Thuny, Franck, Bonaca, Marc P., Cautela, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Primers in Cardio-Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830188/ https://www.ncbi.nlm.nih.gov/pubmed/36636431 http://dx.doi.org/10.1016/j.jaccao.2022.06.008

Ejemplares similares

Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?
por: Kamphuis, Janine A.M., et al.
Publicado: (2019)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
por: Palaskas, Nicolas, et al.
Publicado: (2020)

How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis
por: Rubinstein, Samuel M., et al.
Publicado: (2021)

Strain Imaging in Cardio-Oncology
por: Liu, Jennifer E., et al.
Publicado: (2020)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Primer on Biomarker Discovery in Cardio-Oncology: Application of Omics Technologies
por: Rhee, June-Wha, et al.
Publicado: (2020)

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer
por: Zhang, Lili, et al.
Publicado: (2021)

How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia: A Single-Center Experience
por: Jacob, Robin, et al.
Publicado: (2021)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

CAR T Cell Therapy–Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?
por: Ghosh, Arjun K., et al.
Publicado: (2020)

CARTing Away Cardiac Fibrosis
por: Epstein, Jonathan A.
Publicado: (2020)

Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization
por: O’Quinn, Rupal, et al.
Publicado: (2021)

Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis
por: Witteles, Ronald M.
Publicado: (2021)

Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer
por: Lopez-Mattei, Juan C., et al.
Publicado: (2021)

Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer
por: Kok, Cindy Y., et al.
Publicado: (2021)

Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action
por: Fazal, Muhammad, et al.
Publicado: (2021)

Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology
por: Porter, Charles, et al.
Publicado: (2022)

The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
por: Huang, Yuhsin Vivian, et al.
Publicado: (2022)

Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer
por: Ganatra, Sarju, et al.
Publicado: (2022)

How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations
por: Kambhampati, Swetha, et al.
Publicado: (2023)

Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023)

Developing a Model for Cross-Institutional Educational Collaborations: The Chicago Cardio-Oncology Consortium (CCC) Experience
por: Minga, Iva, et al.
Publicado: (2023)

Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
por: Deharo, Francois, et al.
Publicado: (2023)

Management of Immune Checkpoint Inhibitor–Induced Myocarditis: The French Working Group’s Plea for a Pragmatic Approach
por: Thuny, Franck, et al.
Publicado: (2021)

Rediscovery of magnetocardiography for diagnostic screening and monitoring of treatment response in cardiology
por: Heidecker, Bettina
Publicado: (2023)

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
por: Anker, Markus S., et al.
Publicado: (2020)

Long‐term survivors of early breast cancer treated with chemotherapy are characterized by a pro‐inflammatory biomarker profile compared to matched controls
por: Tromp, Jasper, et al.
Publicado: (2020)

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
por: de Boer, Rudolf A., et al.
Publicado: (2020)

Palpitations in the Cancer Patient
por: Essa, Hani, et al.
Publicado: (2021)

Chest Pain in the Cancer Patient
por: Tyebally, Sara, et al.
Publicado: (2022)

Dyspnoea in Oncological Patients: A Brain Teaser
por: Keramida, Kalliopi, et al.
Publicado: (2023)

Cancer and Postradiotherapy Cardiotoxicity: How to Face Damage in Women’s Hearts?
por: Peix, Amalia, et al.
Publicado: (2023)

The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus
por: Gent, David G, et al.
Publicado: (2023)

Cardio-oncology in 2022
por: Dobson, Rebecca
Publicado: (2023)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

What happens when a patient’s aorta falls off?
por: Spurr, Matthew, et al.
Publicado: (2020)

The Role of Angiotensin‐Converting Enzyme Inhibitors and β‐Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients
por: Brown, Sherry‐Ann, et al.
Publicado: (2020)

Cardiovascular guidelines based on high-quality evidence: Are we getting there?
por: van Dijk, Wouter B, et al.
Publicado: (2019)

Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies
por: Stein-Merlob, Ashley F., et al.
Publicado: (2021)

Simultaneous Left Ventricular Volume and Strain Changes During Chemotherapy Associate With 2‐Year Postchemotherapy Measures of Left Ventricular Ejection Fraction
por: Suerken, Cynthia K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pgtd383j2mv54kgkchrhssnut7